Antiseizure medicines are the foundation of epilepsy treatment for most people, yet reliable access to them remains profoundly unequal around the world. The problem is not simply whether a medicine has been invented or appears on a national formulary. Real access means the right medicine is consistently available, affordable, quality-assured, appropriately prescribed and reachable without repeated disruption.
For millions of people with epilepsy, that chain breaks somewhere between national policy and the pharmacy shelf.
The World Health Organization estimates that around three quarters of people with epilepsy in low-income countries do not receive the treatment they need. In some settings the treatment gap approaches 90%. WHO also reports that average public-sector availability of generic antiseizure medicines in low- and middle-income countries is below 50%.
This means epilepsy can remain uncontrolled not because treatment is scientifically unavailable, but because the medicine never reaches the person who needs it.
Availability is not the same as access
A medicine may be approved nationally and still be absent from local clinics. It may be stocked in a city hospital but unavailable in rural pharmacies. It may be technically available but unaffordable. It may be affordable but repeatedly out of stock. It may be stocked in the wrong formulation or dose strength for the patient who needs it.
Access therefore has several dimensions: selection, procurement, price, distribution, quality, prescribing, reimbursement and continuity.
WHO’s 2024 report on access to medicines for neurological disorders uses epilepsy as a tracer condition precisely because it exposes how these health-system barriers interact.
Epilepsy is highly treatable — if treatment is actually available
WHO estimates that up to 70% of people with epilepsy could live seizure-free with appropriate diagnosis and treatment.
This makes the treatment gap especially important. The problem is not that epilepsy is usually untreatable. The problem is that many people cannot reliably reach effective treatment.
In low-resource settings, the difference between controlled and uncontrolled epilepsy can therefore be determined as much by supply chains and health financing as by neurology.
Essential medicines lists matter — but they are only the first step
The WHO Model List of Essential Medicines identifies priority medicines that health systems should aim to make continuously available, in appropriate dosage forms, of assured quality and at prices patients and systems can afford.
Antiseizure medicines have long been included on the Model List because of their high clinical value and cost-effectiveness.
However, inclusion on an essential medicines list does not guarantee that a medicine will be available in a particular clinic. National lists must still be translated into procurement, budgets, distribution contracts, storage systems and prescribing practice.
National selection shapes what clinicians can prescribe
Countries adapt the WHO Model List to local disease burden, budgets and treatment guidelines. If an antiseizure medicine is excluded from a national essential medicines list or reimbursement scheme, access can become restricted even if the medicine is licensed.
This matters especially for newer medicines that may be clinically important for selected patients but are more expensive than older first-line treatments.
The goal is not to stock every available antiseizure medicine everywhere. It is to ensure that national selection reflects clinical need and that people who require specialist options have a referral route to obtain them.
Older antiseizure medicines remain crucial globally
Medicines such as phenobarbital, carbamazepine, valproate and phenytoin remain central to epilepsy treatment in many lower-resource settings because they are effective, familiar and relatively inexpensive.
WHO has repeatedly highlighted the cost-effectiveness of older first-line antiseizure medicines. In some settings, annual treatment with phenobarbital can cost only a few US dollars.
Low cost, however, does not automatically produce reliable supply.
Carbamazepine is among the most widely available worldwide
An International League Against Epilepsy global survey involving more than 100 countries found major income-related differences in antiseizure medicine availability. Among the first-generation medicines surveyed, carbamazepine was reported as one of the most widely available.
At least one older antiseizure medicine was widely available in most responding countries, but the number of available choices fell substantially in middle- and low-income settings.
Second- and third-generation medicines were even less accessible.
A single available medicine is not enough
Epilepsy is not one condition requiring one drug. Different seizure types, epilepsy syndromes, ages, comorbidities, reproductive considerations and previous treatment responses require different options.
A health system may report antiseizure medicines as ‘available’ while providing only one or two choices that are unsuitable for some patients.
For example, a medicine effective for focal seizures may not be appropriate for certain generalised epilepsies. Pregnancy potential, liver disease, kidney disease, psychiatric history and drug interactions can also affect selection.
Meaningful access therefore requires a clinically useful range, not just a token supply.
Newer medicines are much less evenly distributed
Levetiracetam, lamotrigine, lacosamide and other newer antiseizure medicines have expanded treatment options, often with different interaction profiles and tolerability advantages.
But the ILAE global access survey found that newer medicines are far less available in lower-income countries than in wealthier ones.
This creates a second treatment gap within the first: some people can access basic epilepsy medication but not the medicine best suited to their clinical situation.
Price can make a technically available medicine inaccessible
The retail price of antiseizure medicines does not necessarily fall in proportion to national income. The ILAE survey found that average retail prices were not dramatically lower in poorer countries despite large differences in income.
This means the same medicine can consume a much larger share of household resources in a low-income setting.
Even inexpensive medicines can become unaffordable when treatment is lifelong and must compete with food, housing, transport and other healthcare costs.
Out-of-pocket payment widens inequality
Where medicines are not fully covered by public systems or insurance, patients may pay directly at the pharmacy.
Families then face a recurring expense every month or every few weeks. When seizures are controlled and the benefit of treatment is less visible, financial pressure can tempt people to stretch prescriptions, skip doses or stop treatment.
This is not simply an adherence problem. It can be a health-financing problem.
The indirect costs can be greater than the medicine itself
Travelling to a clinic, paying for a consultation, losing wages, arranging childcare and reaching a distant pharmacy may cost more than the tablets.
Rural patients can therefore face a much larger total cost than urban patients even when the official medicine price is identical.
This is one reason treatment gaps are consistently higher in rural settings.
Stock-outs create dangerous instability
Antiseizure medicines need continuity. Repeated supply interruptions can turn a stable treatment plan into cycles of seizure control and relapse.
Stock-outs may result from inaccurate forecasting, procurement delays, currency shortages, transportation problems, regulatory bottlenecks, conflict, disaster or poor inventory management.
WHO’s neurological medicines report identifies supply-chain weakness as a major barrier to sustained treatment.
Running out can be more dangerous than never starting
Some antiseizure medicines should not be stopped abruptly. Sudden interruption can trigger breakthrough seizures, seizure clusters or status epilepticus in susceptible people.
Patients who cannot obtain their usual medicine may reduce the dose, take it less often or alternate days to make the supply last longer.
This creates unstable drug exposure and can undermine seizure control.
Continuity should be designed into procurement
Health systems often focus on whether a medicine is on the formulary rather than whether it remains continuously available.
For epilepsy, procurement should account for chronic use, predictable refill needs and the risks of abrupt interruption.
Buffer stocks, realistic forecasting, multiple suppliers and better inventory systems can all reduce disruption.
Rural distribution is a separate challenge from national procurement
A country may successfully purchase antiseizure medicines centrally but still fail to distribute them reliably to district clinics.
Road quality, fuel costs, storage conditions, staffing and weak logistics systems can all reduce availability at the last mile.
National warehouse stock therefore does not equal patient access.
Primary-care availability matters
Most people with stable epilepsy do not need to collect every prescription from a tertiary neurology centre.
WHO supports diagnosing and treating many people with epilepsy at primary-care level, especially where neurologists are scarce.
For this model to work, essential antiseizure medicines must actually be stocked where primary-care teams work.
Task sharing fails if medicine supply fails
Training non-specialist clinicians can reduce the epilepsy treatment gap, but only if those clinicians can prescribe and obtain the medicines they are trained to use.
A nurse or primary-care doctor who correctly identifies epilepsy but has no medicine to offer cannot close the treatment gap.
Workforce expansion and medicine access therefore have to develop together.
Phenobarbital illustrates how regulation can restrict access
Phenobarbital is inexpensive and effective for several seizure types, but international and national controlled-drug regulations can complicate procurement and prescribing.
WHO has previously highlighted regulatory barriers affecting phenobarbital availability in some countries.
The challenge is to maintain appropriate safeguards while avoiding rules that unintentionally block access to essential treatment.
Controlled-drug policy can have unintended consequences
Some medicines used in epilepsy are subject to tighter storage, prescribing or import controls. These rules may be justified by misuse or diversion concerns, but excessive complexity can delay legitimate clinical access.
Remote clinics may avoid stocking medicines if record-keeping or storage requirements are difficult to meet.
Balanced regulation is therefore part of medicine-access policy.
Generic medicines are central to global access
Generic competition can reduce prices and widen supply. For chronic conditions such as epilepsy, quality-assured generics are essential to making long-term treatment affordable at population scale.
WHO’s essential medicines framework explicitly supports selection and procurement strategies that improve access to quality-assured, cost-effective medicines.
However, low price should never come at the expense of quality assurance.
Quality problems can undermine trust and seizure control
Substandard or falsified medicines can contain the wrong amount of active ingredient, degrade during poor storage or fail quality standards.
WHO has noted that circulation of substandard or counterfeit products can limit epilepsy care in some settings.
Quality assurance, reliable manufacturers and strong regulatory systems are therefore part of access — not separate from it.
Patients may notice changes between manufacturers
Most approved generic medicines are expected to meet bioequivalence standards, but patients may notice differences in tablet appearance, packaging or excipients when manufacturers change.
For some people, changes can create anxiety or confusion, especially when several medicines are taken together.
Clear counselling and consistent labelling can reduce errors when procurement contracts change suppliers.
Modified-release formulations require particular attention
Immediate-release and modified-release versions of the same active ingredient are not always interchangeable on the same dosing schedule.
Supply systems need to distinguish formulation as well as medicine name and strength.
An apparent substitution can become a clinical error if release characteristics are ignored.
Paediatric formulations are often harder to obtain
Children may require liquid medicines, dispersible tablets or smaller dose strengths.
A country may report a medicine as available while lacking a formulation suitable for infants or young children.
This can force caregivers to split tablets inaccurately or rely on compounded preparations that may not be consistently available.
Weight-based dosing makes paediatric access more complex
Children grow, and doses may need adjustment. Access therefore requires not only the medicine but also ongoing clinical review and suitable strengths.
Stable supply is especially important in severe childhood epilepsies where missed doses can lead to frequent seizures or status epilepticus.
Pregnancy changes which medicines are appropriate
Medicine access cannot be separated from reproductive safety. Some antiseizure medicines carry higher fetal risks than others, and regulatory policies increasingly restrict their use in people who can become pregnant.
A health system that stocks only a narrow range may leave clinicians with difficult choices.
Access to safer alternatives, contraception where appropriate, folic acid and preconception counselling should therefore be considered part of equitable epilepsy treatment.
Valproate creates a particularly difficult global access problem
Valproate is highly effective for some generalised epilepsies but carries important pregnancy-related risks.
In wealthy health systems, risk-reduction programmes may include specialist review, documentation and access to alternative medicines.
In lower-resource settings, removing valproate without ensuring affordable effective alternatives could worsen seizure control for some patients.
Global safety policy therefore has to consider both teratogenic risk and treatment access.
Specialist medicines should not become an urban privilege
People with drug-resistant epilepsy may need medicines outside the basic primary-care formulary.
If those medicines are available only in capital-city hospitals, rural patients face repeated travel and cost barriers.
Referral and dispensing systems should therefore separate the question of who initiates a specialist medicine from where stable repeat supplies can safely be collected.
Drug-resistant epilepsy should not be confused with medicine inaccessibility
A person whose seizures continue because they cannot obtain treatment reliably does not necessarily have drug-resistant epilepsy.
Drug resistance requires failure of adequate, appropriately chosen and tolerated medicine trials.
If treatment has been interrupted repeatedly by stock-outs, cost or poor access, apparent treatment failure may partly reflect the health system rather than the biology of the epilepsy.
Accurate medication histories matter
In fragmented systems, patients may receive different drugs from different clinics without a unified record.
This can lead to duplication, interactions and uncertainty about which treatments have truly been tried.
Better record systems support both safer prescribing and more accurate identification of drug resistance.
Medicine access shapes epilepsy surgery access too
Before epilepsy is labelled drug-resistant, clinicians need confidence that appropriate medication trials have actually been possible.
In settings where only one or two medicines are reliably available, patients may never complete a standard treatment pathway.
This can delay referral for epilepsy surgery and other advanced care.
Humanitarian crises expose fragile supply chains
Conflict, disaster and displacement can interrupt medicine imports, damage warehouses, close pharmacies and displace health workers.
People who previously had stable access may suddenly face complete treatment interruption.
This is why continuity of antiseizure medicines is a central issue in humanitarian epilepsy care.
Migration can create a different access problem
A person may move from a country where their medicine is readily available to one where the brand, formulation or drug itself is difficult to obtain.
Prescription rules and reimbursement systems may also change.
Cross-border continuity therefore depends on generic names, transferable records and rapid access to replacement prescriptions.
Currency crises and inflation can destabilise medicine supply
Countries that depend heavily on imported pharmaceuticals can experience shortages when foreign currency becomes scarce or exchange rates deteriorate.
Even if the medicine remains physically available, rapid price increases can place it beyond household budgets.
Medicine security therefore intersects with national economic stability.
Local manufacturing can improve resilience — if quality is maintained
Domestic pharmaceutical production may reduce dependence on imports and shorten supply chains.
However, manufacturing capacity must be accompanied by strong regulatory oversight and quality assurance.
The policy objective is resilient access to effective medicines, not simply local production for its own sake.
Forecasting requires good data
Health systems need to know how many people are being treated, which medicines are prescribed, how quickly stock is used and where shortages occur.
Without reliable consumption and disease data, procurement becomes guesswork.
Under-ordering causes stock-outs; over-ordering wastes scarce budgets and can lead to expiry.
National epilepsy registries are not required for basic improvement
Perfect data systems are not a prerequisite for better forecasting. Routine pharmacy records, district consumption reports and standardised treatment protocols can already improve planning.
The important step is to treat antiseizure medicine supply as a predictable chronic-care need rather than an occasional specialist purchase.
Community pharmacies can widen access
Where regulation permits, community pharmacies can reduce travel burdens and make repeat supply more convenient.
This model works best when prescriptions are clear, supply is quality-assured and pharmacists can identify problems such as duplicate therapy or formulation mismatch.
For remote populations, decentralised dispensing may significantly improve continuity.
Telemedicine cannot solve a stock-out
Remote neurological advice can support diagnosis and prescribing, but it cannot substitute for physical medicine supply.
This is an important limitation of digital health. A virtual consultation is useful only if the prescribed treatment can actually be obtained.
Digital expansion therefore needs to be matched by supply-chain investment.
Stigma can suppress demand as well as supply
Medicine may be available but unused if people fear being identified as having epilepsy or believe treatment is ineffective or harmful.
WHO identifies stigma and poor awareness as contributors to the treatment gap.
Community education can therefore improve access by increasing willingness to seek diagnosis and continue treatment.
Traditional and biomedical care often coexist
In many settings, people consult traditional or spiritual healers as well as medical services.
This should not automatically be framed as irrational or incompatible with biomedical care. The practical concern is whether treatment is delayed, medicines are stopped or harmful substances are used.
Respectful communication can help maintain antiseizure treatment while acknowledging cultural beliefs.
Medicine access is also a rights issue
WHO’s neurological action plan frames access to essential medicines as part of universal health coverage and equitable neurological care.
People should not experience preventable seizures simply because they live in a rural district, have low income or were born in a country with a weak pharmaceutical supply chain.
Access therefore sits at the intersection of public health, health financing and human rights.
What better access would look like
A strong system would select clinically appropriate essential antiseizure medicines, finance them sustainably, procure quality-assured products, distribute them reliably to primary care, maintain buffer stocks, provide suitable paediatric formulations, support specialist alternatives and protect patients from catastrophic out-of-pocket costs.
It would also train clinicians to choose medicines appropriately and maintain records so treatment failures are interpreted correctly.
Most importantly, it would measure continuity rather than simply whether a medicine appears on a national list.
The central inequality
The same epilepsy can have very different outcomes depending on whether medicine supply is stable.
One person may collect the same prescription every month without thinking about the supply chain behind it. Another may travel for hours, find the medicine out of stock, buy a partial pack privately and then ration tablets until the next shipment arrives.
The biology of their epilepsy may be similar. Their access to treatment is not.
What this page does — and does not — explain
This page focuses on global access to antiseizure medicines: availability, affordability, procurement, regulation, quality and continuity. Clinical selection of individual medicines is covered on the Treatment Options and Medication Side Effects and Interactions pages. Humanitarian shortages and cross-border continuity are covered separately in the humanitarian and migration sections.
Sources
World Health Organization — Epilepsy fact sheet
WHO — Improving access to medicines for neurological disorders
WHO — Better access to medicines for neurological disorders
WHO Model List of Essential Medicines, 2025
ILAE Task Force on Access to Treatment — worldwide availability and affordability of antiseizure medications
WHO/ILAE/IBE — Epilepsy: a public health imperative
Evidence checked: September 2026.